iCAD, Inc.
4 Townsend West
Suite 17
Nashua
New Hampshire
03063
United States
Tel: 603-882-5200
Fax: 603-880-3843
Website: http://www.icadmed.com/
335 articles about iCAD, Inc.
-
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
10/27/2022
iCAD, Inc. today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on November 10, 2022.
-
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
8/29/2022
iCAD, Inc. today announced that a growing number of hospitals and imaging centers in the U.S. and Europe are increasingly choosing to adopt iCAD’s Breast AI Suite, which includes ProFound AI ® , ProFound AI ® Risk, and PowerLook ® Density Assessment, via a subscription model.
-
iCAD Reports Financial Results For Second Quarter 2022
8/10/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2022.
-
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
7/27/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.
-
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
7/13/2022
iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLook® Density Assessment , and ProFound AI® Risk , in booth #AI-20 at the European Congress of Radiology (ECR), July 13-17 in Vienna.
-
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
6/6/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City.
-
iCAD Announces CFO TransitionStephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately
5/25/2022
iCAD, Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief Financial Officer (CFO), effective immediately.
-
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
5/18/2022
iCAD, Inc. announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis will be presented at the Society of Breast Imaging Breast Imaging Symposium, taking place May 16-19 in Savannah, GA.
-
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
5/11/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported its financial and operating results for the three months ended March 31, 2022.
-
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
4/27/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.
-
iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions
4/21/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2022.
-
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
4/5/2022
iCAD, Inc. announced that additional patients have been treated under the international multi-center GLIOX trial and customers globally are continuing to expand use of intraoperative radiation therapy for the treatment of multiple tumor types, including brain, rectal, and head and neck cancers using the Xoft® Electronic Brachytherapy System®.
-
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) MeetingWorld-leading breast cancer AI solutions featured for demonstration in iCAD booth
3/14/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of Breast AI solutions, including ProFound AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and Management Systems Society (HIMSS) Global Health Conference & Exhibition.
-
iCAD to Present at the 42nd Annual Cowen Health Care Conference
3/1/2022
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the virtual 42nd Annual Cowen Health Care Conference, taking place March 7-9, 2022.
-
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021
2/28/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported its financial and operating results for the three and 12 months ended December 31, 2021.
-
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/8/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced the Company will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15-17, 2022.
-
iCAD Announces the Appointment of New Members to its Board of Directors
1/11/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced it has appointed Dana Brown and Timothy Norris Irish as new independent members of the Board of Directors, effective January 10, 2022.
-
iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues
1/4/2022
iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and full year of 2021.
-
iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event
12/23/2021
iCAD, Inc. today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th , 2022.
-
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
12/14/2021
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the first patient with recurrent glioblastoma (GBM) was treated with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at Providence Saint John’s Health Center in Santa Monica, CA.